Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference

LAUSANNE, Switzerland, April 16, 2015 /PRNewswire/ --

Debiopharm International SA (Debiopharm), part of Debiopharm Group^™, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that preclinical data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 12,3 inhibitor) will be presented at the 2015 Annual meeting of the American Association for Cancer Research (AACR) taking place in Philadelphia.

"Oncology has and will continue to benefit from combined and targeted therapies. Results from these preclinical studies underscore the potential clinical value of our two anti-cancer targeted therapies," said Dr Nigel McCracken, Vice President, Translational Medicine. "Currently both Debio 1143 and Debio 1347 are in Clinical Development and Debiopharm remains committed to exploring new combinations and new indications to provide improved benefit to patients suffering from cancers."

AACR 2015 Abstract 

   
    Compound                        Title                       Date and Time     No.

    Debio 1143  SMAC mimetic and radiotherapy synergize to      Sun, Apr 19,     #283
                enhance antitumor immunity in lung cancer by    1:00 - 5:00 pm
                 targeting immunosuppressive cells                

                Debio 1143 synergizes with taxanes,             Mon, Apr 20,     #2529
                topoisomerase and bromodomain inhibitors to     1:00 - 5:00 pm
                inhibit growth of lung adenocarcinoma          

                The IAP inhibitor Debio 1143 reverses           Mon, Apr 20,     #2700
                carboplatin resistance in ovarian cancer cells  1:00 - 5:00 pm
                by inducing both apoptosis and necroptosis     

    Debio 1347  Characterization of two novel oncogenic         Sun, Apr 19,     #689
                FGFR2 fusions sensitive to the FGFR-selective   1:00 - 5:00 pm
                inhibitor Debio 1347 in cholangiocarcinoma

                Formulation switch and pharmacokinetics/        Mon, April 20,   Abstract
                pharmacodynamics of Debio 1347 (CH5183284), a   8:00 - 12:00 am  CT228
                novel FGFR inhibitor, in a first-in-human dose
                escalation trial in solid tumors patients

                Additional poster regarding Debio 1347 to be    Sun, Apr 19,     Abstract
                presented by Chugai Pharmaceutical, the         1:00 - 5:00 pm   #123
                originator of the compound: Mechanism of
                oncogenic signal activation by the novel
                fusion kinase FGFR3-BAIAP2L1

About Debiopharm International SA 

Debiopharm Group^™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.

For more information, please visit: http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
[email protected]
Tel: +41(0)21-321-01-11

Additional Media Contacts
In London
Maitland
Martin Barrow
[email protected]
Tel: +44(0)20-7395-0444

In New York
Russo Partners, LLC
Marissa Goberdhan
Account Executive
[email protected]
Tel: +1-212-845-4253

SOURCE Debiopharm Group